Guggenheim raises First Tracks stock price target to $110 on celiac data

Guggenheim raised its price target for First Tracks Biotherapeutics (TRAX) to $110 from $100, citing positive Phase Ib trial results for ANB033 in celiac disease. The stock trades at $46.34 with a $1.95B market cap, though some analysts suggest it may be overvalued. The company plans further studies and presentations, with additional analyst upgrades also reported.

Original reporting
Published Nov 4, 2026, 8:57 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 9:07 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$TRAX
Bullish
high confidence
Mentioned
$TRAX
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$TRAXBullishMed
01

Why it matters

Analyst upgrades and new Phase Ib data provide fresh catalyst for the stock.

02

Market read

The article introduces new clinical data and a price target increase, offering a fresh trading catalyst for TRAX.

03

What to watch

Potential dilution from recent capital raise and the need for Phase II data in 2027.

Relevance 8/10Novelty 8/10Timing: today

Background

First Tracks Biotherapeutics (TRAX) is a clinical‑stage biotech developing the anti‑CD122 antibody ANB033.

Company-level read

Ticker impact

$TRAXBullishHigh confidence
Context

Guggenheim raised its price target to $110 after First Tracks reported positive Phase Ib celiac disease trial results for ANB033.

Expected impact

likely upward pressure as investors price in increased success probability.

Evidence & confidence

Analyst upgrade and fresh clinical data are new material that can move the share price immediately.

Market effects

Positive biotech trial results may lift sentiment across early‑stage biotech peers.

Limited to U.S. biotech sector.

Modest; primarily affects investors focused on clinical‑stage biotech.

Counterpoint

If the trial data does not translate into later‑stage success, the price target may be premature.

Key entities

  • Guggenheim

    Raised price target to $110 and maintained Buy rating.

  • First Tracks Biotherapeutics

    Reported positive Phase Ib results for ANB033 in celiac disease.

Related articles

$TRAXHighAI 8/10

First Tracks Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

First Tracks Biotherapeutics, Inc. (TRAX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 First Tracks Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update • Announced ANB033 achieved a statistically significant and clinically meaningful protective effect on both gluten-induced intestinal damage and symptoms in Cohort

$TRAXMedAI 8/10

First Tracks Biotherapeutics (TRAX) Reports Positive ANB033 Celiac Cohort Results

First Tracks Biotherapeutics (TRAX) reported positive Phase 1b trial results for ANB033 in celiac disease, showing significant protection against gluten-induced damage. The company expects mucosal-healing data in Q1 2027 and eosinophilic esophagitis results in Q3 2027. It also anticipates late-stage trials for celiac disease and Phase 2 trials for vitiligo in 2027. The company raised $200 million in a private placement, bringing pro forma cash to $343 million.

$TRAXMedAI 9/10

First Tracks Biotherapeutics reports positive Phase 1b ANB033 topline results in celiac disease

First Tracks Biotherapeutics reported positive Phase 1b results for ANB033, showing significant protection against gluten-induced intestinal damage in celiac disease patients. The treatment reduced IEL density, improved histology, and lowered symptom scores. No severe adverse events were reported. The company plans to advance ANB033 to late-stage development in 2027, with Cohort 2 data expected in Q1 2027.